| Literature DB >> 31398943 |
Francesca Di Cara1, Pierre Andreoletti2, Doriane Trompier2, Anne Vejux2, Margret H Bülow3, Julia Sellin3, Gérard Lizard2, Mustapha Cherkaoui-Malki2, Stéphane Savary4.
Abstract
The immune response is essential to protect organisms from infection and an altered self. An organism's overall metabolic status is now recognized as an important and long-overlooked mediator of immunity and has spurred new explorations of immune-related metabolic abnormalities. Peroxisomes are essential metabolic organelles with a central role in the synthesis and turnover of complex lipids and reactive species. Peroxisomes have recently been identified as pivotal regulators of immune functions and inflammation in the development and during infection, defining a new branch of immunometabolism. This review summarizes the current evidence that has helped to identify peroxisomes as central regulators of immunity and highlights the peroxisomal proteins and metabolites that have acquired relevance in human pathologies for their link to the development of inflammation, neuropathies, aging and cancer. This review then describes how peroxisomes govern immune signaling strategies such as phagocytosis and cytokine production and their relevance in fighting bacterial and viral infections. The mechanisms by which peroxisomes either control the activation of the immune response or trigger cellular metabolic changes that activate and resolve immune responses are also described.Entities:
Keywords: immune response; immunometabolism; inflammation; peroxisome; phagocytosis; virology
Mesh:
Substances:
Year: 2019 PMID: 31398943 PMCID: PMC6721249 DOI: 10.3390/ijms20163877
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
A list of bona fide peroxisomal proteins (A) and proteins with an ambiguous peroxisomal localization (B) that are expressed in the immune cells and tissues and suggested to participate in the regulation of the immune response.
|
| |||||
|
|
|
|
|
|
|
|
| Fatty acid oxidation ABC transporter | Phagocytosis? | Microglia (BV-2) | m | [ |
| CD14+ monocytes | h | [ | |||
| Macrophages | h | [ | |||
| PBMCs | h | [ | |||
|
| Fatty acid oxidation ABC transporter | Phagocytosis? | Microglia (BV-2) | m | [ |
| Macrophages (peritoneal) | m | [ | |||
| PBMCs | h | [ | |||
|
| Fatty acid oxidation ABC transporter | ABCD1 compensation | PBMCs | h | [ |
|
| Fatty acid oxidation | Antiviral response | T lymphoma (Jurkat E6.1) | h | [ |
|
| Fatty acid oxidation | Phagocytosis? | Microglia (BV-2) | m | [ |
|
| Lipid metabolism | Cell proliferation, | Bone marrow | h | [ |
| Myeloid leukemia cells | h | [ | |||
|
| Antioxidant system | Cell proliferation | Lymph nodes | h | [ |
| T lymphoma (Jurkat E6.1) | h | [ | |||
| Myeloid leukemia cells U937 | h | [ | |||
| T hybridoma (2B4), B lymphoma A20, mast cell P815 | m | [ | |||
| Microglia (BV-2) | m | [ | |||
| Macrophages | d | [ | |||
|
| Peroxisome biogenesis | Mitochondrial and peroxisomal fission | Microglia progenitor cells | h | [ |
|
| Ether lipid synthesis | Cell proliferation | Thymocytes | m | [ |
|
| RIG-I-like receptor (RLR) adaptor | Antiviral response | Macrophages | m | [ |
|
| Fatty acid oxidation | Inflammation | Microglia (brain) | m | [ |
| Macrophages (Raw) | m | [ | |||
|
| Antioxidant system | Brucellosis pathogenesis | Dendritic cells and monocytes | m | [ |
| CRL 2471 spleen macrophages | m | [ | |||
|
| Peroxisome biogenesis | Inflammation | Macrophages | m | [ |
| d | [ | ||||
|
| Peroxisome biogenesis | Inflammation | Macrophages | m | [ |
| d | [ | ||||
|
| Peroxisome biogenesis | Inflammation | Macrophages | m | [ |
|
| |||||
|
|
|
|
|
|
|
|
| Fatty acid oxidation | Inflammation | Neutrophils, monocytes/macrophages, dendritic cells | h | [ |
| Macrophages (differentiated THP-1) | h | [ | |||
| Lymph nodes, spleen | h | [ | |||
| Macrophages, dendritic cells, neutrophils | m | [ | |||
|
| Regeneration of NADPH | Hematopoietic differentiation | CD34+ bone marrow cells | h | [ |
| Bone marrow mononuclear cells | h | [ | |||
| Macrophages (THP-1, | h | [ | |||
|
| Antioxidant system | Neuroinflammation | Brain | r | [ |
* h: human, m: mouse, r: rat, d: Drosophila.
Figure 1Peroxisomal metabolites and immunity. The metabolites influenced by peroxisomal function (in bold) with downstream processes or derived metabolites (listed in grey boxes) with examples of their roles in the immune system activation and regulation are depicted. Peroxisomal β-oxidation is both involved in the degradation and synthesis of polyunsaturated fatty acids (PUFAs). Moreover, peroxisomes are needed for the production of plasmalogens (ether lipids), which in turn are a source for PUFAs. Arachidonic acid is used for the production of eicosanoids with proinflammatory (prostaglandins, leukotrienes, thromboxanes) or anti-inflammatory functions (lipoxins). Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) serve as precursors for resolvins, protectins, and maresins, which are important for the resolution of inflammation. Furthermore, peroxisomes are needed for the regulation of overall fatty acid composition by degrading very long-chain fatty acids (VLCFAs) and regulating the catabolism of LCFAs/MCFAs. Additionally, peroxisomes are involved in cholesterol homeostasis, intracellular trafficking of cholesterol, and the balance of free and esterified cholesterol. Oxysterols, formed through enzymatic or non-enzymatic cholesterol oxidation, are impacted by the redox balance in the cell, which depends on peroxisomal function. Peroxisomes are involved in the degradation and production of polyamines and might play a role in the degradation and production of other yet unknown modulators of the immune system.
Figure 2Peroxisomes, oxidative stress and inflammation. Oxidative stress can be the result of increased reactive oxygen species (ROS) production or a decreased antioxidant potential. The defective peroxisomes increase ROS production and reduce the antioxidant ability of the cell. The dysfunctional peroxisomes result also in overall lipid alterations, like the accumulation of VLCFAs and VLCFA-cholesteryl esters. In Drosophila tissue with no functional peroxisomes, the accumulation of free fatty acids was observed. These lipid metabolic defects contribute to mitochondrial damage and swelling, leading to increased ROS production which in turn causes protein carbonylation, lipoxidation, glycoxidation and oxysterol formation, inducing stress pathways and inflammation. Lipid metabolic dysregulation in mammalian systems also causes inflammation via the induction of Toll like receptor (TLR) and Protein kinase C (PKC)-mediated NF-κB signaling.
Figure 3Peroxisomes and aging. (A) Mitochondria undergo cycles of fusion and fission, resulting in mitochondrial networks or fragmented mitochondria, respectively. If fission is decreased and mitochondria form a network (e.g., as a result of dietary restriction or AMPK activation, or mutation of Vps1 and Fis1 in yeast), lifespan increases. However, when the mitochondrial fission machinery is reintroduced, but targeted exclusively to peroxisomes (e.g., by overexpression of a Pex15-Fis1 fusion protein, lower right panel), or when peroxisomal functions are missing altogether (e.g., by additional mutation of the peroxisomal biogenesis factor Pex5, lower left panel), lifespan extension is lost, even though mitochondria are still forming a network. (B) A summary of the current understanding of the effect of peroxisome activity on aging. Peroxisomes’ effect on aging is linked to the production of reactive oxygen species (ROS): The proper activity of the peroxisomal ROS scavenging enzyme catalase is essential to promote longevity by reducing oxidative stress, while overall peroxisomal abundance (peroxisomal biogenesis) increases oxidative stress and therefore promotes aging.
Figure 4Peroxisomes in an antiviral response. (A) Peroxisomes are signaling hubs for the induction of a Type III interferon response by harboring the antiviral signaling protein MAVS. Viral nucleic acids are recognized (1) by the membrane receptors like the Toll like receptors (TLRs) 3, 7, 8 and 9, or by (2) cytosolic receptors (RIG-1 like receptors, RLR). RLRs activate mitochondrial antiviral signaling adaptor (MAVS) to defeat viruses. The location of MAVS on either mitochondria or peroxisomes leads to different responses: (3) mitochondrial MAVS responds via IRF3 and NF-κB signaling, leading to initiation of Type I interferon response, while (4) peroxisomal MAVS can initiate a Type III interferon response. (B) Some viruses utilize strategies to target peroxisomes in order to circumvent the immune response. Hepatitis C (HepC) and Human cytomegalovirus (HCMV) target the MAVS function, thereby inhibiting the Type III interferon response. HCMV viral protein vMIA interacts with Pex19 in order to target MAVS. Certain flaviviruses and HIV target peroxisomal biogenesis factors, thereby inhibiting overall peroxisomal functions. In addition, the HIV protein Nef interacts with peroxisomal ACOT8, which interferes with antigen presentation and T cell activation. Some viral proteins localize to peroxisomes: the pestivirus protein N-terminal protease is located on peroxisomes and targets the Type I interferon response by inhibiting IRF3 function, and the Hepatitis B (HepB) protein HBx localizes to peroxisomes and seems to promote hepatocellular carcinogenesis.
Figure 5An overview of immune processes regulated by peroxisomes. The overall lipid perturbations in membranes due to peroxisomal defects (indicated by red circles) could impact the function of membrane-localized receptors and signaling between the cells (top: outside-in signaling examples including pattern recognition and pro-inflammatory signals, bottom: inside-out signaling examples including antigen presentation and secretion of immune system mediators). The altered composition of membrane lipids also influences membrane properties relevant for vesicular trafficking (phagocytosis, endocytosis, lysosomal function etc.) and functions of the inner and outer mitochondrial membranes. Peroxisomal functions impact on the immune pathways, like NF-κB and MAPK, which regulate the production of immune regulators such as cytokines and antimicrobial peptides (AMPs). While a direct link between peroxisomal defects and NLRP3 activation has not been demonstrated so far, peroxisomes may influence the function of the NLRP3 inflammasome. Peroxisomes contribute to the secretion of immune system mediators (like IL-1β, which is regulated by the inflammasome, but also many other pro- and anti-inflammatory cytokines, including TNFα, and lipid mediators with pro- and anti-inflammatory capacity). Peroxisomes impact on ROS signaling, play a role in phagocytosis regulation (including regulation of the actin cytoskeleton), and in the antiviral interferon-mediated response. Peroxisomes closely cooperate with mitochondria (red double arrow) with respect to membrane contact sites, ROS production, and lipid exchange, thereby influencing energy metabolism and lipid catabolism.